UT MD Anderson CCOP Research Base

描述(由申请人提供)：自第一届NCI获奖以来 1987年，德克萨斯大学安德森癌症中心社区 临床肿瘤学计划(MDACCOP)研究基地已管理150个临床 5000多名患者参加了试验，其中包括2688名患者 化学预防试验。MDACCOP研究基地将继续 产生和支持一系列癌症控制的临床研究， 预防和治疗可以有效地在 社区环境。研究基地及其附属CCOP网站有 全力支持和机构资源，包括临床研究 基础设施，马建联，世界？S规模最大，排名最高 综合性癌症中心。提出了以下具体目标： 1.为附属CCOP和MBCCOP提供MDACC临床试验的访问权限。 2.从学术中心转移信息、技术和标准 对社区的影响。 3.加强开展预防和控制试验，包括 行为干预、化学预防试验、症状控制、 确定癌症或癌症复发风险增加的个人 他们的癌症，以及社区健康结果研究的发展 布景。 4.将妇科肿瘤组(GOG)CCOP整合到MDACCOP RB中； 使当前的MDACCOP能够访问GOG研究并加入 另一家RB(作为第5家附属公司)。 5.开发新的方法，在 多机构环境，如远程症状评估，并建立 在中国开展这些研究的教育支持系统 社区。 6.提供战略，以增加少数群体成员的招聘 小组和妇女参加临床和癌症控制试验。 7.维护一个全面的数据管理系统，将千年发展目标与 附属CCOP和MBCCOP。该系统保证了数据的准确采集和处理 传输用于研究试验的信息，并提供设施以 加强持续质量保证、数据监控和现场审计。 8.与NCI社区肿瘤学和预防试验研究小组合作 确保RB的研究计划与RB的目标一致 国家计划。

DESCRIPTION (provided by applicant): Since the awarding of its first NCI Grant in 1987, the University of Texas M.D. Anderson Cancer Center Community Clinical Oncology Program (MDACCOP) Research Base has managed 150 clinical trials involving more than 5,000 patients, including 2,688 patients entered onto chemoprevention trials. The MDACCOP Research Base will continue to generate and support a spectrum of clinical studies of cancer control, prevention and therapy that can be implemented and conducted efficiently in a community environment. The Research Base and its affiliated CCOP sites have the full support and institutional resources, including the clinical research infrastructure, of the MDACC, the world?s largest and highest ranked comprehensive cancer center. The following specific aims are proposed: 1. Provide affiliate CCOPs and MBCCOPs access to MDACC clinical trials. 2. Transfer information, technology, and standards from the academic centers to the community. 3. Enhance the development of prevention and control trials that include behavioral interventions, chemoprevention trials, symptom control, the identification of individuals at increased risk for cancer or recurrence of their cancer, and the development of health outcomes research in the community setting. 4. Integrate the Gynecology Oncology Group (GOG) CCOPs into the MDACCOP RB; enable the current MDACCOPs to access the GOG studies and affiliate with another RB (as a 5th affiliate). 5. Develop new methodologies for answering cancer control questions in a multi-institutional setting, such as remote symptom assessment, and establish the educational support systems for initiation of these studies in the community. 6. Provide strategies to increase the recruitment of members of minority groups and women for clinical and cancer control trials. 7. Maintain a comprehensive data management system that links MDACC to the affiliate CCOPs and MBCCOPs. This system ensures the accurate collection and transmission of information for research trials and provides a facility to enhance ongoing quality assurance, data monitoring, and on-site audits. 8. Work with the NCI Community Oncology and Prevention Trials Research Group to ensure the research programs of the RB are congruent with the goals of the national program.